Skip to main content
SpringerLink
Log in

Exploration of the Potential Biomarker FNDC5 for Discriminating Heart Failure in Patients with Coronary Atherosclerosis

  • Original Article
  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

Coronary atherosclerosis leading to ischemic artery disease is one of the etiological factors to develop heart failure (HF). This study aimed to investigate potential biomarkers for discriminating HF in atherosclerotic patients. This study included 40 consecutive atherosclerotic patients who underwent angiography. Concentrations of B-type natriuretic peptide (BNP), fibronectin type III domain containing 5 (FNDC5), and Phosphodiesterase 9A (PDE9A) were measured in 20 atherosclerotic patients with HF symptoms/signs and 20 without HF symptoms/signs. Circulating BNP levels were elevated, while FNDC5 levels were reduced in atherosclerotic patients with HF symptoms/signs compared to those without HF symptoms/signs. Pearson correlation analysis showed a significant correlation between FNDC5 and BNP. Receiver Operating Characteristics analysis indicated that both FNDC5 and BNP were able to discriminate HF in atherosclerotic patients. Our findings suggest that FNDC5, along with BNP, has independent value as a biomarker for discriminating HF in patients with coronary atherosclerosis.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

Patients’ data are available upon reasonable request.

Abbreviations

AUC:

Areas under the curve

BNP:

B-type natriuretic peptide

CAD:

Coronary artery disease

CI:

Confidence interval

FNDC5:

Fibronectin type III domain containing 5

HF:

Heart failure

HFpEF:

Heart failure patients with preserved ejection fraction

LVEF:

Left ventricular ejection fraction

NYHA:

New York Heart Association

PDE9A:

Phosphodiesterase 9A

ROC:

Receiver operating characteristics

References

  1. GBD 2017 disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7.

    Article  Google Scholar 

  2. Fernandes VRS, Cheng S, Lima JAC. Atherosclerosis imaging and heart failure. Heart Fail Rev. 2006;11:279–88. https://doi.org/10.1007/s10741-006-0229-7.

    Article  PubMed  Google Scholar 

  3. Jain CC, Borlaug BA. Performance and interpretation of invasive hemodynamic exercise testing. Chest. 2020;158:2119–29. https://doi.org/10.1016/j.chest.2020.05.552.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gevaert AB, Kataria R, Zannad F, et al. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart. 2022;108:1342–50. https://doi.org/10.1136/heartjnl-2021-319605.

    Article  PubMed  Google Scholar 

  5. Adamson PD, Hunter A, Madsen DM, et al. High-sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes. 2018;11:e004227. https://doi.org/10.1161/circoutcomes.117.004227.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cwikiel J, Seljeflot I, Fagerland, et al. High-sensitive cardiac Troponin T and exercise stress test for evaluation of angiographically significant coronary disease. Int J Cardiol. 2019;287:1–6. https://doi.org/10.1016/j.ijcard.2019.04.019.

    Article  PubMed  Google Scholar 

  7. Meijers WC, Bayes-Genis A, Mebazaa A. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). Eur J Heart Fail. 2021;23:1610–32. https://doi.org/10.1002/ejhf.2346.

    Article  CAS  PubMed  Google Scholar 

  8. Yasue H, Yoshimura M, Sumida H. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203. https://doi.org/10.1161/01.cir.90.1.195.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang X, Hu C, Wu HM, et al. Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target. Acta Pharmacol Sin. 2021;42:1390–400. https://doi.org/10.1038/s41401-020-00557-5.

    Article  CAS  PubMed  Google Scholar 

  10. Ritterhoff J, Tian R. Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nat Rev Cardiol. 2023. https://doi.org/10.1038/s41569-023-00887-x. (Online ahead of print).

    Article  PubMed  Google Scholar 

  11. Lee DI, Zhu G, Sasaki T, et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015;519:472–6. https://doi.org/10.1038/nature14332.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cao RY, Zheng H, Hong Y, et al. Cardiac rehabilitation with targeted intensity improves cardiopulmonary functions accompanying with reduced copeptin level in patients with coronary artery disease. J Cardiovasc Transl Res. 2021;14:317–26. https://doi.org/10.1007/s12265-020-10055-y.

    Article  PubMed  Google Scholar 

  13. McDonagh TA, Metra M, Adamo M, et al. ESC scientific document group, 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368.

    Article  CAS  PubMed  Google Scholar 

  14. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145:e895–1032. https://doi.org/10.1161/CIR.0000000000001063.

    Article  PubMed  Google Scholar 

  15. Korta P, Pocjec E, Mazur-Bialy A. Irisin as a multifunctional protein: implications for health and certain diseases. Medicina. 2019;55:485. https://doi.org/10.3390/medicina55080485.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Benomar K, Espiard S, Loyer C, Jannin A, Vantyghem MC. Atrial natriuretic hormones and metabolic syndrome: recent advances. Presse Med. 2018;47:116–24. https://doi.org/10.1016/j.lpm.2017.12.002.

    Article  PubMed  Google Scholar 

  17. Abd EI-Mottaleb NA, Galal HM, EI Maghraby KM, Gadallah AI. Serum irisin level in myocardial infarction patients with or without heart failure. Can J Physiol Pharmacol. 2019;97:932–8. https://doi.org/10.1139/cjpp-2018-0736.

    Article  CAS  Google Scholar 

  18. Matsuo Y, Gleitsmann K, Mangner N, et al. Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines. J Cachexia Sarcopenia Muscle. 2015;6:62–72. https://doi.org/10.1002/jcsm.12006.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Lecker SH, Zavin A, Cao P, et al. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. Circ Heart Fail. 2012;5:812–8. https://doi.org/10.1161/CIRCHEARTFAILURE.112.969543.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yu Q, Kou W, Xu X, et al. FNDC5/Irisin inhibits pathological cardiac hypertrophy. Clin Sci (Lond). 2019;133:611–27. https://doi.org/10.1042/CS20190016.

    Article  CAS  PubMed  Google Scholar 

  21. Maak S, Norheim F, Drevon CA, Erickson HP. Progress and challenges in the biology of FNDC5 and Irisin. Endocr Rev. 2021;42:436–56. https://doi.org/10.1210/endrev/bnab003.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Cao RY, Zheng H, Redfearn D, Yang J. FNDC5: a novel player in metabolism and metabolic syndrome. Biochimie. 2019;158:111–6. https://doi.org/10.1016/j.biochi.2019.01.001.

    Article  CAS  PubMed  Google Scholar 

  23. Ho JE, Zern EK, Wooster L, et al. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions. Circulation. 2019;140:353–65. https://doi.org/10.1161/circulationaha.118.039136.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138:861–70. https://doi.org/10.1161/circulationaha.118.034646.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Hashemi D, Mende M, Trippel TD, et al. Evaluation of the HFA-PEFF score: results from the prospective DIAST-CHF cohort. ESC Heart Fail. 2022;9:4120–8. https://doi.org/10.1002/ehf2.14131.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Wijk SS, Aizpurua AB, Rocca HB, et al. The HFA-PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23:838–40. https://doi.org/10.1002/ejhf.2019.

    Article  Google Scholar 

  27. Pocock SJ, Ferreira JP, Packer M, et al. Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur J Heart Fail. 2022;24:1869–78. https://doi.org/10.1002/ejhf.2607.

    Article  CAS  PubMed  Google Scholar 

  28. Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J. 2005;26:241–9. https://doi.org/10.1093/eurheartj/ehi036.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

All authors are grateful to young physicians including residents from the Department of Cardiology, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University for their dedications to collect clinical data.

Funding

This work was supported by the National Natural Science Foundation of China [grant number 81672260 for RYC] and Xuhui Healthcare System Peak Discipline Construction Funding Project of Shanghai [grant number SHXHZDXK202305 for HZ & PM]. The funding sources were not involved in study design; in the analysis and interpretation of data; and in the decision to submit the article for publication.

Author information

Author notes

  1. Hongchao Zheng and Yuntao Zheng contributed equally to this study.

Authors and Affiliations

  1. Biomarker Exploring Program, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, 966 Middle Huaihai Road, Shanghai, 200031, China

    Hongchao Zheng, Lingling Jiang, Siyu Liu, Peizhi Miao, Ning Zhu & Richard Y. Cao

  2. Biomarker Exploring Program, Shanghai Xuhui Dahua Hospital, 901 Laohumin Road, Shanghai, 200237, China

    Yuntao Zheng & Wei Huang

Authors
  1. Hongchao Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuntao Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lingling Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Siyu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peizhi Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ning Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Richard Y. Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Hongchao Zheng and Richard Y. Cao conceptualized, revised, and proofread the manuscript; Hongchao Zheng and Yuntao Zheng prepared the draft; Wei Huang, Lingling Jiang, Peizhi Miao, and Ning Zhu collected and analyzed data; Siyu Liu analyzed data and prepared artwork.

Corresponding author

Correspondence to Richard Y. Cao.

Ethics declarations

Human Subjects/Informed Consent Statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (The Ethics Committee of Shanghai Xuhui Central Hospital, Shanghai, China) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from every patient for being included in the study.

Conflict of Interest

The authors declare that there is no conflict of interests.

Additional information

Associate Editor Junjie Xiao oversaw the review of this article

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zheng, H., Zheng, Y., Huang, W. et al. Exploration of the Potential Biomarker FNDC5 for Discriminating Heart Failure in Patients with Coronary Atherosclerosis. J. of Cardiovasc. Trans. Res. (2024). https://doi.org/10.1007/s12265-024-10489-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12265-024-10489-8

Keywords

Search

Navigation